Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Abiomed, Inc.

Advanced Bionics designs and manufactures cochlear implants and hearing technology, self-described as providing solutions for individuals with hearing loss.

Advanced Bionics

RGB Medical Devices specializes in medical technology, providing equipment for operating rooms, intensive care units, and home care settings. The company has been innovating in this field since 1988 and complies with total quality standards.

RGB Medical Devices

Abiomed develops heart pumps and cardiopulmonary support systems, self-described as focused on heart recovery and saving lives.

Metric
Company Name	Abiomed, Inc.	Advanced Bionics	RGB Medical Devices
Symbol	ABMD
MSH ID	COM:ABIOMED	COM:ADVANCEDBIONICS	COM:RGB-MEDICAL
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Devices	Medical Devices	Medical Devices
Country	US	US	DE
Stage
Employee Count	2.00K
Website	abiomed.com	advancedbionics.com	rgb-medical.com
LinkedIn			rgb-medical-devices-s-a-
Founders

Metric
Market Cap	17.18B
Enterprise Value
Monthly Web Traffic		33.21K	46
Web Traffic Growth		-0.65	0.15
Valuation
Raised Capital

Metric
Revenue	1.03B
Revenue (LTM)
Revenue (NTM)
Gross Profit	843.60M
EBITDA	400.78M
Operating Income	372.69M
Net Income	136.50M
EPS	3
Diluted EPS	2.98
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82
Operating Profit Margin	0.36
EBITDA Margin	0.39
Net Profit Margin	0.13
Return on Equity	0.10
Return on Assets	0.08
Return on Capital Employed	0.24

COM:ABIOMED

Abiomed

Last Close

381.02

21/12 21:00

Market Cap

17.18B

Beta: -

Volume Today

15.70M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	126.85
P/B Ratio	11.52
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	16.65
EV Multiple	43.20

Metric
Days Sales Outstanding	32.05
Days Payables Outstanding	68.57
Days Inventory Outstanding	182.31
Operating Cycle	214.36
Cash Conversion Cycle	145.80
Asset Turnover	0.62

Metric
Operating Cash Flow	285.39M
Free Cash Flow	249.63M
Cash Flow to Debt
Operating Cash Flow/Sales	0.28
Free Cash Flow Yield	0.01

Metric
Cash & Equivalents	132.82M
Accounts Receivable	5.33M
Inventory	93.98M
Goodwill	76.79M
Debt to Capitalization
Debt to Assets
Current Ratio	7.05
Quick Ratio	6.13

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05
R&D to Revenue	0.16
SG&A to Revenue